Freek Verheul

Gouda, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Early clinical markers of aggressive multiple sclerosis.

Early clinical markers of aggressive multiple sclerosis.

Journal: Brain : a journal of neurology

Published: August 22, 2019

Risk of secondary progressive multiple sclerosis: A longitudinal study.

Risk of secondary progressive multiple sclerosis: A longitudinal study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: August 10, 2019

Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study.

Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study.

Journal: Multiple sclerosis and related disorders

Published: September 11, 2018

Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.

Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.

Journal: JAMA neurology

Published: August 08, 2018

Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.

Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: April 07, 2017

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.

Journal: Brain : a journal of neurology

Published: February 07, 2017

Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice.

Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: November 26, 2016

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

Journal: The Lancet. Neurology

Published: August 31, 2016

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: May 17, 2016

Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis.

Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: May 12, 2016

Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.

Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.

Journal: Neurology. Clinical practice

Published: April 23, 2016

Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse.

Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse.

Journal: Journal of neurology

Published: April 09, 2016

Showing 1-12 of 38

Last Updated: 09/26/2026